Expression and Prognostic Value of Lgr5 in Patients with Recurrent Nasopharyngeal Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Lo K, Huang DJS. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12(6):451–462. doi:10.1016/S1044579X02000883
   PubMed Web of Science ®Google Scholar
• Luo W. Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal “unity of ecology and evolution” pathological ecosystem. Theranostics. 2023;13(5):1607–1631. doi:10.7150/thno.82690
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Lu H, et al. Clinical outcomes of salvage endoscopic nasopharyngectomy for patients with advanced recurrent nasopharyngeal carcinoma. Front Oncol. 2021;11:716729. doi:10.3389/fonc.2021.716729
   PubMed Web of Science ®Google Scholar
• Tringale K, Lee NJ. Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. Lancet Oncol. 2021;22(6):e218. doi:10.1016/S1470-2045(21)00238-2
   PubMedGoogle Scholar
• Liu Y, Wen Y, Tang J, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, Phase 3 trial. Lancet Oncol. 2021;22(3):381–390. doi:10.1016/S1470-2045(20)30673-2
   PubMed Web of Science ®Google Scholar
• Na’ara S, Amit M, Billan S, Cohen J, Gil ZJ. Outcome of patients undergoing salvage surgery for recurrent nasopharyngeal carcinoma: a meta-analysis. Ann Surg Oncol. 2014;21(9):3056–3062.
   PubMed Web of Science ®Google Scholar
• Chen M, Wen W, Guo X, et al. Endoscopic nasopharyngectomy for locally recurrent nasopharyngeal carcinoma. Laryngoscope. 2009;119(3):516–522. doi:10.1002/lary.20133
   PubMed Web of Science ®Google Scholar
• Hua Y, Han F, Lu L, et al. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer. 2012;48(18):3422–3428. doi:10.1016/j.ejca.2012.06.016
   PubMed Web of Science ®Google Scholar
• Guan Y, Liu S, Wang H, et al. Long-term outcomes of a Phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma. Chin J Cancer. 2016;35:20. doi:10.1186/s40880-016-0081-7
   PubMedGoogle Scholar
• Han F, Zhao C, Huang S, et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Chin Oncol. 2012;24(8):569–576.
   Google Scholar
• Li W, Lu H, Wang H, et al. Salvage endoscopic nasopharyngectomy in recurrent nasopharyngeal carcinoma: prognostic factors and treatment outcomes. Am J Rhinol Allergy. 2021;35(4):458–466. doi:10.1177/1945892420964054
   PubMed Web of Science ®Google Scholar
• Buchlak Q, Esmaili N, Bennett C, Wang Y, King J, Goldschlager TJP. Predictors of improvement in quality of life at 12-month follow-up in patients undergoing anterior endoscopic skull base surgery. PLoS One. 2022;17(7):e0272147. doi:10.1371/journal.pone.0272147
   PubMed Web of Science ®Google Scholar
• Leung C, Tan SH, Barker N. Recent advances in Lgr5(+) stem cell research. Trends Cell Biol. 2018;28(5):380–391. doi:10.1016/j.tcb.2018.01.010
   PubMed Web of Science ®Google Scholar
• Nagata H, Ishihara S, Abe H, et al. LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer. Br J Cancer. 2019;120(10):996–1002. doi:10.1038/s41416-019-0442-5
   PubMed Web of Science ®Google Scholar
• Jang BG, Kim HS, Chang WY, Bae JM, Kim WH, Kang GH. Expression profile of LGR5 and its prognostic significance in colorectal cancer progression. Am J Pathol. 2018;188(10):2236–2250. doi:10.1016/j.ajpath.2018.06.012
   PubMed Web of Science ®Google Scholar
• Hou MF, Chen PM, Chu PY. LGR5 overexpression confers poor relapse-free survival in breast cancer patients. BMC Cancer. 2018;18(1):219. doi:10.1186/s12885-018-4018-1
   PubMedGoogle Scholar
• Zhang J, Cai H, Sun L, et al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/beta-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res. 2018;37(1):225. doi:10.1186/s13046-018-0864-6
   PubMedGoogle Scholar
• Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima AJM. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod. 2000;6(6):529–534. doi:10.1093/molehr/6.6.529
   PubMed Web of Science ®Google Scholar
• Li W, Lu H, Wang H, et al. Circular RNA TGFBR2 acts as a ceRNA to suppress nasopharyngeal carcinoma progression by sponging miR-107. Cancer Lett. 2021;499:301–313. doi:10.1016/j.canlet.2020.11.001
   PubMed Web of Science ®Google Scholar
• Yang CF, Peng LX, Huang TJ, et al. Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway. Cancer Lett. 2014;344(2):260–271. doi:10.1016/j.canlet.2013.11.006
   PubMed Web of Science ®Google Scholar
• Liao K, Xia B, Zhuang QY, et al. Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-kappaB/COX-2 pathway. Theranostics. 2015;5(3):302–321. doi:10.7150/thno.8387
   PubMed Web of Science ®Google Scholar
• Yang C, Peng J, Jiang W, et al. mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo. Cancer Lett. 2013;341(2):186–194. doi:10.1016/j.canlet.2013.08.004
   PubMed Web of Science ®Google Scholar
• Zhong X, Yang Y, Li B, et al. Downregulation of SLC27A6 by DNA hypermethylation promotes proliferation but suppresses metastasis of nasopharyngeal carcinoma through modulating lipid metabolism. Front Oncol. 2021;11:780410. doi:10.3389/fonc.2021.780410
   PubMed Web of Science ®Google Scholar
• Sinnung S, Janvilisri T, Kiatwuthinon PJM. biochemistry c. Reversal of cisplatin sensitization and abrogation of cisplatin-enriched cancer stem cells in 5–8F nasopharyngeal carcinoma cell line through a suppression of Wnt/β-catenin-signaling pathway. Mol Cell Biochem. 2021;476(4):1663–1672. doi:10.1007/s11010-020-04045-6
   PubMed Web of Science ®Google Scholar
• Zhong Q, Liu ZH, Lin ZR, et al. The RARS-MAD1L1 fusion gene induces cancer stem cell-like properties and therapeutic resistance in nasopharyngeal carcinoma. Clin Cancer Res. 2018;24(3):659–673. doi:10.1158/1078-0432.CCR-17-0352
   PubMed Web of Science ®Google Scholar
• Ko CJ, Li CJ, Wu MY, Chu PY. Overexpression of LGR-5 as a predictor of poor outcome in patients with hepatocellular carcinoma. Int J Environ Res Public Health. 2019;16:10. doi:10.3390/ijerph16101836
   Web of Science ®Google Scholar
• Jaks V, Barker N, Kasper M, et al. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet. 2008;40(11):1291–1299. doi:10.1038/ng.239
   PubMed Web of Science ®Google Scholar
• Barker N, Huch M, Kujala P, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 2010;6(1):25–36. doi:10.1016/j.stem.2009.11.013
   PubMed Web of Science ®Google Scholar
• Morgan RG, Mortensson E, Williams AC. Targeting LGR5 in colorectal cancer: therapeutic gold or too plastic? Br J Cancer. 2018;118(11):1410–1418. doi:10.1038/s41416-018-0118-6
   PubMed Web of Science ®Google Scholar
• Scannell CA, Pedersen EA, Mosher JT, et al. LGR5 is expressed by ewing sarcoma and potentiates wnt/beta-catenin signaling. Front Oncol. 2013;3:81. doi:10.3389/fonc.2013.00081
   PubMedGoogle Scholar
• Li F, Song X, Li X, et al. Lgr5 maintains stemness and regulates cell property in nasopharyngeal carcinoma through Wnt/β-catenin signaling pathway. Stem Cell Res. 2020;47:101916. doi:10.1016/j.scr.2020.101916
   PubMed Web of Science ®Google Scholar
• Wattanawongdon W, Bathpho TS, Tongtawee T. Co-Expression of LGR5 and CD133 cancer stem cell predicts a poor prognosis in patients with gastric cancer. Turk J Gastroenterol. 2021;32(3):261–268. doi:10.5152/tjg.2021.20108
   PubMed Web of Science ®Google Scholar
• Hsu HC, Liu YS, Tseng KC, et al. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis. 2013;28(11):1535–1546. doi:10.1007/s00384-013-1721-x
   PubMed Web of Science ®Google Scholar